



In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research, 2nd Edition

Guest Editors:

Dr. Xuyi Yue

Nemours Children's Hospital,
Delaware, DE 19803, USA

**Dr. Kiran Kumar
Solingapuram Sai**

Department of Radiology, Wake
Forest School of Medicine,
Winston-Salem, NC 27157, USA

Deadline for manuscript
submissions:

30 December 2024

Message from the Guest Editors

Dear Colleagues,

Molecular imaging can provide real-time noninvasive visualization, characterization, and quantification of biological processes at the molecular levels in intact living subjects. Nuclear molecular imaging has been receiving significant attention due to its high sensitivity and noninvasive imaging profile. This Special Issue of *Pharmaceuticals* invites both original and review articles related to in vivo nuclear imaging in drug development and pharmacological research, and we welcome submissions of the following topics: (1) identify and validate in vivo biomarkers by nuclear molecular imaging; (2) evaluation of on-target and off-target effects, receptor occupancy, and biodistribution information of the radiotracers; (3) in vivo biorthogonal reaction involved radioisotopes to probe mechanism of diseases; (4) determine the pharmacokinetic, pharmacodynamic, and metabolic profiles; (5) dosimetry studies, kinetic modeling of radiotracers in pre-clinical research and clinical investigation; (6) bench-to-bedside clinical translation of radiotracers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com